Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: Atherosclerosis - October 22, 2023 Category: Cardiology Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Nov;38(6):797-809. doi: 10.3904/kjim.2023.243. Epub 2023 Oct 20.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy lead...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
Long-term outcomes of liver transplantation for homozygous familial hypercholesterolaemia in Australia and New Zealand
CONCLUSIONS: LT for homozygous FH was highly effective in achieving substantial long-term reduction in LDL-cholesterol concentrations in all nine patients. LT remains an option for severe cases of homozygous FH where drug therapy combined with apheresis is ineffective or unfeasible.PMID:37863699 | DOI:10.1016/j.atherosclerosis.2023.117305 (Source: Atherosclerosis)
Source: Atherosclerosis - October 20, 2023 Category: Cardiology Authors: Michael M Page Winita Hardikar George Alex Sue Bates Shubha Srinivasan Michael Stormon Kat Hall Helen M Evans Peter Johnston John Chen Alan Wigg Libby John Elif I Ekinci Richard C O'Brien Robert Jones Gerald F Watts Source Type: research
Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial
CONCLUSIONS: Inclisiran treatment did not reduce LDL-C levels in patients with homozygous familial hypercholesterolemia despite substantial lowering of PCSK9 levels. Inclisiran was well-tolerated, and the safety findings were consistent with previously reported studies and the overall safety profile.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT03851705.PMID:37850379 | DOI:10.1161/CIRCULATIONAHA.122.063460 (Source: Circulation)
Source: Circulation - October 18, 2023 Category: Cardiology Authors: Frederick Raal Ronen Durst Ran Bi Zsolt Talloczy Pierre Maheux Anastasia Lesogor John J P Kastelein ORION-5 Study Investigators Source Type: research
